450 related articles for article (PubMed ID: 34738855)
1. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial.
Rokhsareh S; Haghighi S; Tavakoli-Ardakani M
J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial.
Aghili M; Darzikolaee NM; Babaei M; Ghalehtaki R; Farhan F; Razavi SZE; Rezaei S; Esmati E; Samiei F; Azadvari M; Farazmand B; Bayani R; Amiri A
J Gastrointest Cancer; 2023 Jun; 54(2):467-474. PubMed ID: 35426033
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
[TBL] [Abstract][Full Text] [Related]
4. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
Smith EM; Pang H; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Fadul CE; Knox C; Le-Lindqwister N; Gilman PB; Shapiro CL;
JAMA; 2013 Apr; 309(13):1359-67. PubMed ID: 23549581
[TBL] [Abstract][Full Text] [Related]
5. Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial.
Aoyama T; Morita S; Kono T; Hata T; Mishima H; Sakamoto J
J Cancer Res Ther; 2021; 17(6):1473-1478. PubMed ID: 34916380
[TBL] [Abstract][Full Text] [Related]
6. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
8. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
Battaglini E; Park SB; Barnes EH; Goldstein D
Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
[TBL] [Abstract][Full Text] [Related]
9. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.
Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Chang SC; Lan YT; Lin CC; Yen CC; Tzeng CH; Wang WS; Chiang HL; Teng CJ; Teng HW
Support Care Cancer; 2012 Jul; 20(7):1491-7. PubMed ID: 21814779
[TBL] [Abstract][Full Text] [Related]
13. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.
Zimmerman C; Atherton PJ; Pachman D; Seisler D; Wagner-Johnston N; Dakhil S; Lafky JM; Qin R; Grothey A; Loprinzi CL
Support Care Cancer; 2016 Mar; 24(3):1071-8. PubMed ID: 26248652
[TBL] [Abstract][Full Text] [Related]
14. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial.
Salehifar E; Janbabaei G; Hendouei N; Alipour A; Tabrizi N; Avan R
Clin Drug Investig; 2020 Mar; 40(3):249-257. PubMed ID: 31925721
[TBL] [Abstract][Full Text] [Related]
18. Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: A randomized controlled trial.
Haroun EA; Mansour NO; Eltantawy A; Shams MEE
Pharmacotherapy; 2023 Sep; 43(9):872-882. PubMed ID: 37199288
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
20. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
